June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

June 6, 2016June 6, 2016

Potential New Avenue for Development of Psoriasis Treatment as Researchers Discover How ADAM17 Works

News

A new study out of Germany could advance the understanding of how an overactive immune system leads to the excess of inflammation that occurs in many different diseases, including psoriasis. ... Read more

May 27, 2016May 27, 2016

Identifying Key Contributors to Psoriasis Disease Progression, Possibly Leading to Future Treatment Targets

News

Psoriasis is a chronic autoimmune disease characterized by excess inflammation of skin cells called keratinocytes, resulting in itching, burning, and stinging sensations of the skin. Excess inflammation of keratinocytes is mediated through the ... Read more

May 25, 2016May 25, 2016

Psoriasis Biosimilar SB2 by Samsung Bioepis Accepted for FDA Review

News

Samsung Bioepis recently announced in a press release that the U.S. FDA has accepted the company’s Biologics License Application for its biosimilar drug candidate SB2, which references Remicade (infliximab). The drug is indicated ... Read more

May 23, 2016May 23, 2016

Independent Psoriasis Registry to Track Safety of Recently Approved Treatment Taltz (Ixekizumab)

News

The Portland, Oregon-based Corrona Psoriasis Registry announced it has been selected to track drug safety reporting for ixekizumab, a new biologic medication developed by global pharma Eli Lilly of Indianapolis, which markets ... Read more

May 20, 2016May 20, 2016

Challenges of Living with Psoriasis Dramatized in New Film ‘Millefeuille’

News

A culmination of its extended research into psoriasis and psoriatic arthritis, global pharmaceutical company Celgene is launching a fictional dramatization highlighting the unhappiness and frustration experienced by patients struggling with ... Read more

May 19, 2016May 19, 2016

Study in Danish Twins ‘Strongly’ Links Psoriasis to Obesity and Type 2 Diabetes

News

A study using data collected from Danish twins found that psoriasis is associated with type 2 diabetes, body mass index and obesity. The findings also indicate a potential common genetic ... Read more

May 17, 2016May 17, 2016

Psoriasis Vulgaris a Distinct Disease from Two Separate but Similar Conditions, According to Genetic Analysis

News

A study published in the latest edition of the journal PLOS one used gene expression microarray analysis of genetic data to compare the genetic similarities and differences between palmoplantar pustulosis psoriasis, ... Read more

May 16, 2016May 16, 2016

Researchers Publish Review of Psoriasis Treatment Methotrexate

News

Scottish researchers published a new meta-analysis of the medical literature evaluating whether the medication methotrexate is safe and effective for treating psoriasis. The research report, “Safety and Efficacy of Methotrexate ... Read more

May 12, 2016May 12, 2016

anti-TNFα Antibodies Could Decrease Microparticles Present in Severe Psoriasis

News

Psoriasis is associated with atherosclerosis, in which circulating microparticles play a key role. A new research study demonstrated that the increased levels of circulating CD41a and CD31 microparticles were unchanged after anti-IL-12/23 ... Read more

May 12, 2016May 19, 2016

Phase 2 Trial of Prurisol for Psoriasis to be Unblinded, Promising Result Expected

News

Cellceutix Corporation recently announced that the clinical database for the phase 2 clinical trial of Prurisol, for treatment of mild-to-moderate chronic plaque psoriasis, will be ‘unblinded’ within the next few ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata